Stock Exchange:
BRUSSELS
Sector:
Biotechnology
Sub-sector:
Development
Turnover last year:
241,2 M€ 2023
Profits last year:
211,7 M€ 2023
Activity: Biotechnology. Antibodies for cystic fibrosis.
GALAPAGOS is an international biotechnology company specializing in the creation and development of antibodies in cystic fibrosis, inflammation, rheumatoid arthritis and intestinal diseases.
http://www.glpg.com/